RecruitingNCT06956755
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
Sponsor
Groupe Francophone des Myelodysplasies
Enrollment
6,990 participants
Start Date
Jul 7, 2003
Study Type
OBSERVATIONAL
Conditions
Summary
The Registry MDS is an ongoing, observational study that has collected longitudinal data on diagnostics, demographics, clinical parameters, and health Care Interventions (HCI) from patients with MDS and therapy-related acute myeloid leukemia
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Male or female
- Age \> 18 years
- Patients with myelodysplastic syndrome and therapy-related acute myeloid leukemia
- Able and willing to provide written informed consent
Exclusion Criteria2
- Age \<18 years
- Patient is unwilling or unable to give consent
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06956755
Related Trials
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222238 locations
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
NCT057965702 locations
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
NCT056365145 locations
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT0425631773 locations
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT066180019 locations